Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

Blood

Volumn 117, Issue 10, 2011, Pages 2935-2943

  Elling, Christian ^a   Erben, Philipp ^b   Walz, Christoph ^b   Frickenhaus, Marie ^a   Schemionek, Mirle ^a   Stehling, Martin ^c   Serve, Hubert ^d   Cross, Nicholas C P ^e   Hochhaus, Andreas ^f   Hofmann, Wolf Karsten ^b   Berdel, Wolfgang E ^a   Müller Tidow, Carsten ^a   Reiter, Andreas ^b   Koschmieder, Steffen ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; IMATINIB; PDGFRA PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79953091929     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-286757     Document Type: Article

References (37)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
2. Erben P, Gosenca D, Muller MC, et al. Screening for diverse PDGFRA or PDGFRB by fusion genes is facilitated by generic quantitative RT-PCR. Haematologica. 2010;95(5):738-744.
3. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319-1325.
4. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357-5364. (Pubitemid 46206989)
5. Kitamura T, Koshino Y, Shibata F, et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol. 2003;31(11):1007-1014. (Pubitemid 37329742)
6. Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105(1):324-334. (Pubitemid 40053100)
7. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117(9):2562-2569. (Pubitemid 47494357)
8. Score J, Walz C, Jovanovic JV, et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia. 2009;23(2):332-339.
9. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest. 2004;84(7):874-883. (Pubitemid 38833247)
10. Medeiros F, Corless CL, Duensing A, et al. KITnegative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28(7):889-894. (Pubitemid 38856844)
11. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest. 2006;86(1):94-100. (Pubitemid 43250972)
12. Modi H, McDonald T, Chu S, Yee JK, Forman SJ, Bhatia R. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood. 2007;109(12):5411-5421. (Pubitemid 46890564)
13. Sargin B, Choudhary C, Crosetto N, et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood. 2007;110(3):1004-1012. (Pubitemid 47267440)
14. Makishima H, Cazzolli H, Szpurka H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009;27(36):6109-6116.
15. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192.
16. Frohling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12(6):501-513. (Pubitemid 350199072)
17. Bazenet CE, Gelderloos JA, Kazlauskas A. Phosphorylation of tyrosine 720 in the platelet-derived growth factor alpha receptor is required for binding of Grb2 and SHP-2 but not for activation of Ras or cell proliferation. Mol Cell Biol. 1996;16(12):6926-6936. (Pubitemid 26389752)
18. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79(4):1283-1316. (Pubitemid 29473317)
19. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch.; 456(2):111-127.
20. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell.;17(1):98-110.
21. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708-710. (Pubitemid 36159485)
22. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125(3):660-667. (Pubitemid 37070684)
23. Debiec-Rychter M, Wasag B, Stul M, et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol. 2004;202(4):430-438. (Pubitemid 38456161)
24. Wasag B, Debiec-Rychter M, Pauwels P, et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol. 2004;17(8):889-894. (Pubitemid 38993772)
25. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn. 2004;6(3):197-204. (Pubitemid 39136646)
26. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-4349. (Pubitemid 46621810)
27. Sakurai S, Hasegawa T, Sakuma Y, et al. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol. 2004;35(10):1223-1230. (Pubitemid 39361645)
28. Yamamoto H, Oda Y, Kawaguchi K, et al. c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). Am J Surg Pathol. 2004;28(4):479-488. (Pubitemid 38436521)
29. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol. 2005;23(1):49-57. (Pubitemid 41702622)
30. Pasini B, Matyakhina L, Bei T, et al. Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. J Clin Endocrinol Metab. 2007;92(9):3728-3732. (Pubitemid 47435362)
31. Schildhaus HU, Cavlar T, Binot E, Buttner R, Wardelmann E, Merkelbach-Bruse S. Inflammatory fibroid polyps harbour mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene. J Pathol. 2008;216(2):176-182.
32. Hiwatari M, Taki T, Tsuchida M, et al. Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor alpha(PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16) (p13q22).Leukemia. 2005;19(3):476-477.
33. Hiwatari M, Ono R, Taki T, et al. Novel gain-offunction mutation in the extracellular domain of the PDGFRA gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23). Leukemia. 2008; 22(12):2279-2280.
34. Rand V, Huang J, Stockwell T, et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A. 2005;102(40):14344-14349. (Pubitemid 41429700)
35. Kumabe T, Sohma Y, Kayama T, Yoshimoto T, Yamamoto T. Overexpression and amplification of alpha-PDGF receptor gene lacking exons coding for a portion of the extracellular region in a malignant glioma. Tohoku J Exp Med. 1992;168(2): 265-269.
36. LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer. 2002;100(1):2-8. (Pubitemid 34602057)
37. Bejcek BE, Voravud N, Deuel TF. Biosynthesis and processing of the platelet derived growth factor type alpha receptor. Biochem Biophys Res Commun. 1993;196(1):69-78. (Pubitemid 23309476)